Sign in

You're signed outSign in or to get full access.

Meghan Joyce

Director at BOSTON BEER COBOSTON BEER CO
Board

About Meghan V. Joyce

Meghan V. Joyce (age 40) is an independent Class A director of The Boston Beer Company (SAM), serving since 2019; she is Chair of the Nominating/Governance Committee and a member of the Audit Committee . She is Co‑Founder and CEO of Duckbill Technologies (since Apr 2022), previously COO and EVP of Platform at Oscar Health (2019–Apr 2022; now Senior Advisor), and earlier held senior roles at Uber, served as a Senior Policy Advisor at the U.S. Treasury, and worked at Bain Capital and Bain & Company . She is recognized by SAM as an “audit committee financial expert” under SEC rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
Oscar Health (NYSE: OSCR)COO and EVP of PlatformSep 2019 – Apr 2022 (Senior Advisor since Apr 2022)Oversaw operations, technology, marketing, clinical operations, and tech/services solutions
Uber TechnologiesRegional GM, U.S. & Canada Cities; East Coast GM; Boston GM2013 – 2019Responsible for business outcomes and rider/driver experience
U.S. Department of the TreasurySenior Policy Advisor2011 – 2012Policy advisory work in Washington, D.C.
Bain CapitalInvestorN/AInvestment experience
Bain & CompanyConsultantN/AStrategy/consulting background

External Roles

OrganizationRoleCommittees
Guardant Health, Inc. (NASDAQ: GH)Director (appointed Aug 2021)Audit Committee; Compensation Committee

Board Governance

  • Independence and roles: Joyce is an independent director; only independent directors may serve on SAM’s Audit, Compensation, and Nominating/Governance Committees . Current SAM roles: Nominating/Governance Committee (Chair) and Audit Committee .
  • Audit Committee financial expertise: SAM’s Board determined all four current Audit Committee members, including Joyce, are “audit committee financial experts” (SEC definition) .
  • Attendance and engagement: The Board held 5 regular meetings in FY2024; each director attended at least 75% of Board and committee meetings, and all directors attended the 2024 annual meeting . The Audit Committee held 4 regular meetings in 2024; the Nominating/Governance Committee held 4 regular meetings in 2024 .
  • Executive sessions and leadership: Independent directors met in executive session four times during FY2024; the Lead Director (Julio Nemeth) leads these sessions .
  • Committee evolution: With the announced retirement of director Jean‑Michel Valette in May 2025, committee and chair assignments will be reset at the May 2025 meetings (affects Audit Chair vacancy) .
  • Governance policy enhancements: In 2024, SAM added a formal Chairman succession protocol (recommended by Nom/Gov) and updated Corporate Governance Guidelines, including an overboarding policy .

Fixed Compensation (Non-Employee Director – FY2024)

Component2024 Amount ($)Notes
Cash retainer + committee retainers105,000 SAM’s schedule: $75,000 base retainer; $20,000 committee chair; $10,000 per committee membership (non-chair). Joyce’s mix aligns with Nom/Gov Chair (+$20k) and Audit member (+$10k) .
Option awards (grant-date fair value)65,173 Annual non-employee director option award per schedule (~$65k) . Options fully vested at grant under Director Equity Plan .
RSU awards (grant-date fair value)65,017 Annual RSU award per schedule (~$65k) . RSUs vest one year from grant, contingent on continued service .
Total235,190
  • Director compensation schedule (adopted Feb 2023): Annual cash retainer $75,000; committee chair $20,000; committee member $10,000; Lead Director $20,000; annual equity: options ($65k) and RSUs ($65k); one‑time option and RSU awards (~$65k each) upon first-time election or appointment .
  • FY2024 grants: On May 7, 2024, each non-employee director elected at that time (including Joyce) received options to purchase 568 Class A shares at a $268.20 exercise price; options are fully vested at grant; RSU grants of 243 units vest in one year .

Performance Compensation

  • Performance linkage to director pay: None disclosed. Director RSUs are time-based (one-year vest), and options vest immediately; there are no performance metrics tied to director equity awards under the Director Equity Plan .
  • Executive plan context (for comparison only): Company uses Depletions Growth, Net Revenue Growth (CAGR), EBIT (adjusted), and Focused Cost Savings for executive incentive programs; these do not apply to director compensation .

Other Directorships & Interlocks

CompanyTypeCommittee RolesPotential Interlock/Conflict with SAM
Guardant Health, Inc.Public company boardAudit; Compensation No SAM-related transactions disclosed; no related-party concerns noted for Joyce

Expertise & Qualifications

  • Skills cited by SAM as relevant: Business strategy, managing growth, financial modeling, modern consumer recruitment/engagement, digital marketing/technology implementation, and managing/retaining diverse employee groups .
  • Governance credentials: Chair of Nominating/Governance since May 2020; Audit Committee member since 2019; prior service on Compensation Committee (2019–2020) . Recognized as an “audit committee financial expert” .

Equity Ownership

ItemDetail
Beneficial ownership (Class A)4,932 shares; represents less than 1% of outstanding Class A shares .
Components (per footnote)Includes options to acquire 4,485 Class A shares (currently exercisable/within 60 days) and 243 unvested RSUs .
Unexercised option shares (aggregate)4,485 option shares held at FY2024 year-end (director-level table) .
2024 equity grants243 RSUs (vest in 1 year) and 568 options at $268.20 exercise price; options fully vested at grant .
Hedging/pledgingProhibited for directors; annual certification; company reports no known violations since policy adoption .
Ownership guidelinesTarget Ownership = 4x annual base director cash fee; “shares” include beneficially owned shares and unvested RSUs, but exclude unexercised options; as of Feb 2025, 4 directors met the target and 6 had not (no director-specific status disclosed) .

Governance Assessment

  • Board effectiveness and engagement: Joyce holds two high‑leverage governance roles (Nom/Gov Chair; Audit member) and is designated an Audit Committee financial expert—positive for oversight of risk, audit, and governance frameworks . Attendance thresholds were met, and committee work was active (Audit and Nom/Gov each met four times in 2024) .
  • Independence and conflicts: She is expressly independent; only independent directors serve on committees . SAM reports no related‑party transactions since Jan 1, 2024 other than specified Dogfish‑related items (none involving Joyce) .
  • Incentive alignment: Director equity is split between immediately‑vested options ($65k grant-date value) and one‑year RSUs ($65k), plus cash fees (her 2024 cash = $105k); approximate mix ~45% cash / ~55% equity, using grant-date values . Ownership guidelines (4x cash fee; unvested RSUs count; options excluded) promote alignment, though individual compliance status is not disclosed .
  • Policy safeguards: Strong prohibitions against hedging/pledging and an updated overboarding policy enhance investor protections; no known policy violations .
  • RED FLAGS: None disclosed specific to Joyce (no related‑party transactions, no attendance shortfall, no hedging/pledging, and committees limited to independent directors) .

Appendix: Reference Tables

Director Compensation (FY2024)

MetricAmount ($)
Fees Paid in Cash105,000
Option Awards (grant‑date fair value)65,173
RSU Awards (grant‑date fair value)65,017
Total235,190

Director Equity Detail (FY2024 actions and holdings)

ItemDetail
Option grant (annual)568 shares at $268.20 exercise price on May 7, 2024; fully vested at grant .
RSU grant (annual)243 RSUs on May 7, 2024; vests one year from grant contingent on service .
Unexercised option shares held (aggregate)4,485 shares .

Beneficial Ownership (as of record date in 2025 proxy)

HolderShares Beneficially OwnedPercent of Class
Meghan V. Joyce4,932 <1%

Committee Assignments (as of 2025 proxy mailing)

CommitteeRole
Nominating/GovernanceChair
AuditMember; designated “audit committee financial expert”

Policy Highlights

  • Insider Trading Policy: Prohibits hedging/pledging; annual certification; no known violations .
  • Director Ownership Guidelines: Target = 4x annual base director fee; counts unvested RSUs; excludes unexercised options; 4 directors at/above target; 6 below (no individual disclosure) .